Phaseline

Targets › TP53

TP53 (Cellular tumor antigen p53): drug programs, companies and trials

22 programs from 20 companies in 36 trials: 17 Phase 1, 10 Phase 2, 8 Phase 3, 1 Phase 4; Oncology, Infectious disease; next expected readout Dec 2026.

Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence. Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. (UniProt, P04637)

Open in Phaseline: the race on TP53, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PrecigenZopapogene imadenovec
p53 gene therapy delivered via adenoviral vector
TP53Phase 4Recurrent Respiratory PapillomatosisDec 2027
Shanghai Jiao Tong University School of MedicineFludarabine, Busulfan and Melphalan (Flu-Bu-Mel)
Dual alkylating agents with purine nucleoside analog; busulfan and melphalan are DNA-alkyl
FLT3, TP53Phase 3Acute Myeloid Leukemia; ToxicitiesDec 2026
Kartos TherapeuticsNavtemadlin (KRT-232)
Tumour suppressor p53/oncoprotein Mdm2 inhibitor
TP53, MDM2Phase 3Myelofibrosis; Polycythemia Vera; Endometrial Cancer; Diffuse Large B Cell Lymphoma …Dec 2026
Sun Yat-sen UniversityTPF induction chemotherapy
Combination chemotherapy: polymeric micellar paclitaxel (taxane microtubule inhibitor), ci
Tubulin, TP53Phase 3Nasopharyngeal CarcinomaDec 2026
First Affiliated Hospital, Sun Yat-Sen UniversityConcurrent Chemotherapy (Cisplatin)
Platinum-based alkylating agent
TP53Phase 3Locally Advanced Nasopharyngeal CarcinomaAug 2027
First Affiliated Hospital, Sun Yat-Sen UniversityInduction Chemotherapy (TPF regimen)
Docetaxel, cisplatin, and 5-fluorouracil combination
Tubulin, TP53, TYMS, RRM1Phase 3Locally Advanced Nasopharyngeal CarcinomaAug 2027
OSE ImmunotherapeuticsOSE2101
peptidic cancer vaccine with nine HLA-A2-restricted epitopes targeting tumor-associated an
TP53, ERBB2, CEA, MAGEA2, MAGEA3Phase 3Patients With Non-Small Cell Lung Cancer; Solid Advanced TumorDec 2027
Institute of Hematology & Blood Diseases Hospital, ChinaDVRd
Daratumumab (CD38 monoclonal antibody), Velcade (proteasome inhibitor), and dexamethasone
PSMD1, TP53, MYCPhase 2Multiple MyelomaDec 2026
SynerGene TherapeuticsSGT-53
p53 gene therapy delivered by lipid nanoparticles
TP53Phase 2Metastatic Pancreatic CancerDec 2026
Centre Leon BerardSiremadlin (HDM201)
Tumour suppressor p53/oncoprotein Mdm2 inhibitor
TP53, MDM2Phase 2Malignant Solid Tumor; Advanced Soft-tissue SarcomaFeb 2027
City of Hope Medical CenterModified Vaccinia Virus Ankara Vaccine Expressing p53
p53 tumor antigen vaccine using modified vaccinia virus ankara
TP53Phase 2Recurrent Platinum-Resistant Fallopian Tube Carcinoma; Adult Solid NeoplasmApr 2027
Fondazione Ricerca TraslazionaleTedopi
Cancer vaccine inducing cytotoxic T-lymphocytes against tumor-associated antigens (CEA, p5
CEA, TP53, ERBB2, MAGE2, MAGE3Phase 2Metastatic Non Small Cell Lung CancerSep 2027
Sarcoma Oncology Research Center, LLCTrabectedin
Alkylating agent that binds to DNA and induces cell death
TP53Phase 2Sarcoma; Advanced Soft Tissue SarcomaDec 2030
Medical University of ViennaCisplatin
DNA-damaging platinum agent; primary mechanism through DNA crosslinking and induction of a
TP53Phase 2Uterine Cervical NeoplasmsApr 2031
PMV Pharmaceuticalsrezatapopt
p53 reactivator selective for TP53 Y220C mutation
TP53Phase 1Advanced Solid Tumor; TP53 Y220C Mutation; Myelodysplastic SyndromeDec 2026
Chinese PLA General HospitalTP53-EphA-2-CAR-DC
TP53 mutant peptide-loaded, EphA2-targeting CAR dendritic cell vaccine
TP53, EPHA2Phase 1Solid Tumor, AdultDec 2026
Jacobio PharmaceuticalsJAB-30355
TP53 Y220C mutant-selective stabilizer
TP53Phase 1Solid TumorsJan 2027
AeRang KimAlrizomadlin (APG-115)
Tumour suppressor p53/oncoprotein Mdm2 inhibitor
TP53, MDM2Phase 1Malignant Peripheral Nerve Sheath Tumor (MPNST)Oct 2027
City of Hope Medical CenterMinnelide
Triptolide analog; prodrug that releases triptolide via phosphatase activation; inhibits R
TP53Phase 1Advanced Lung Non-Small Cell CarcinomaOct 2027
Clasp TherapeuticsCLSP-1025
HLA-A*02:01 specific T cell engager targeting p53 R175H mutation
TP53Phase 1Advanced Solid TumorDec 2027
Changchun GeneScience PharmaceuticalGenSci128
TP53 Y220C mutant stabilizer
TP53Phase 1Solid Tumors Harboring a TP53 Y220C MutationDec 2027
Nutshell Therapeutics (Shanghai)NTS071
TP53 Y220C mutant stabilizer
TP53Phase 1Advanced Solid TumorsDec 2028

Conditions

Acute Myeloid Leukemia (4) Advanced Solid Tumor (2) Locally Advanced Nasopharyngeal Carcinoma (2) Nasopharyngeal Carcinoma (2) Malignant Solid Tumor (1) Advanced Soft-tissue Sarcoma (1) Sarcoma (1) Advanced Soft Tissue Sarcoma (1) Multiple Myeloma (1) Metastatic Pancreatic Cancer (1) TP53 Y220C Mutation (1) Myelodysplastic Syndrome (1)

Modalities

small molecule (12), mixed (6), other (1)

Companies

First Affiliated Hospital, Sun Yat-Sen University (2) City of Hope Medical Center (2) Centre Leon Berard (1) Sarcoma Oncology Research Center, LLC (1) Institute of Hematology & Blood Diseases Hospital, China (1) SynerGene Therapeutics (1) PMV Pharmaceuticals (1) Kartos Therapeutics (1) Precigen (1) OSE Immunotherapeutics (1) Medical University of Vienna (1) Sun Yat-sen University (1) Fondazione Ricerca Traslazionale (1) Shanghai Jiao Tong University School of Medicine (1) AeRang Kim (1) Changchun GeneScience Pharmaceutical (1) Nutshell Therapeutics (Shanghai) (1) Chinese PLA General Hospital (1) Jacobio Pharmaceuticals (1) Clasp Therapeutics (1)

Related targets

MDM2 (3) Tubulin (2) ERBB2 (2) CEA (2) PSMD1 (1) MYC (1) TYMS (1) RRM1 (1) MAGEA2 (1) MAGEA3 (1) MAGE2 (1) MAGE3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.